A Nation-Wide Evaluation of Suboptimal Lipid-Lowering Treatment Patterns Among Patients Undergoing Intervention for Acute Coronary Syndrome in Hungary
Authors:
- Gergely Gyorgy NagyGNGergely Gyorgy Nagy
- Laszlo MarkLMLaszlo Mark
- Andrea GerencserAGAndrea Gerencser
- Istvan ReiberIRIstvan Reiber
- Norbert KissNKNorbert Kiss
- Gyorgy RokszinGRGyorgy Rokszin
- Ibolya FabianIFIbolya Fabian
- Zoltan CsanadiZCZoltan Csanadi
- Istvan KaradiIKIstvan Karadi
- Daniel AradiDADaniel Aradi
- Laszlo BajnokLBLaszlo Bajnok
- Gyorgy ParaghGPGyorgy Paragh
Open Access
- 31 October 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (21) , 6562
Abstract
Background/Objectives: A significant gap exists between guideline recommendations and everyday practice. Stringent treatment is needed for vulnerable patients with acute coronary syndrome (ACS). Methods: Data on the lipid-lowering therapy (LLT), including the adherence, persistence, and mortality of patients undergoing percutaneous coronary intervention or bypass surgery in Hungary in 2018 were followed up and analyzed based on the National Health Insurance Fund database until the end of 2020. Results: A total of 12,997 patients underwent revascularization for ACS in 2018, whose discharge therapy included any LLT, a high- or moderate-intensity statin, or ezetimibe at a proportion of 91%, 75%, 12%, and 4%, respectively. By the end of the observation period, the frequency of ezetimibe administration increased to 11%. Persistence decreased, reaching 50% for all therapeutic regimens by month 16. Patients on moderate statin doses had a significantly higher mortality rate at the end of follow-up than those receiving high-intensity statin with (20% vs. 9%, p < 0.0001) or without (20% vs. 14%, p = 0.00029) ezetimibe. Those taking less potent statin doses had higher rates of comorbidities; for example, a minimum of three comorbidities were present in 39% of patients taking medium statin doses and 23% among those on high-intensity statin therapy (p < 0.0001). Conclusions: LLT persistence decreased during follow-up. The administration of a higher-intensity lipid-lowering regimen was associated with better persistence and adherence, along with more favorable mortality rates. Multimorbidity was associated with the use of lower statin doses. The results suggest that more attention is needed in terms of lipid control of females, elderly people, and individuals with several comorbidities, and emphasis should be placed on improving persistence and increasing the frequency of combined LLT prescriptions.Keywords
Funding Information
- Novartis Hungary Ltd.
This publication has 42 references indexed in Scilit:
- Characteristics of patients with recurrent acute myocardial infarction after MINOCAProgress in Cardiovascular Diseases, 2023
- LDL-cholesterol target levels achievement in high-risk patients: An (un)expected gender biasNutrition, Metabolism and Cardiovascular Diseases, 2023
- Combination Lipid-Lowering Therapy in Patients Undergoing Percutaneous Coronary InterventionJACC, 2023
- Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI studyThe Lancet Regional Health - Europe, 2023
- Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP)Progress in Cardiovascular Diseases, 2023
- 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease RiskJACC, 2022
- High-Intensity Statin Use Among Patients With Atherosclerosis in the U.S.JACC, 2022
- Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational studyAtherosclerosis, 2021
- Gender Disparities in Health Resource Utilization in Patients with Atherosclerotic Cardiovascular Disease: A Retrospective Cross-Sectional StudyAdvances in Therapy, 2019
- Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or EzetimibeJAMA Network Open, 2018